Email ID
Sign me in automatically next time
Repros gets partial reprieve on Proellex hold

The US FDA reclassified the clinical hold on Repros Therapeutics' studies for its orally selective progesterone antagonist Proellex from a full hold to partial status to permit the firm to conduct a...
10 October 2012
Donna Young

Please Login to read the full article.
04 April 2016
Stockholm, Sweden
06 April 2016
Hamburg, Germany
JOB OF THE WEEK Promote your job vacancy
© 2016 Informa plc. All rights reserved.
This site is owned and operated by Informa plc ("Informa") whose registered office is Mortimer House, 37-41 Mortimer Street, London, W1T 3JH. Registered in England and Wales. Number 3099067. UK VAT Group: GB 365 4626 36